Mahmoudvand Golnaz, Rouzbahani Arian Karimi, Kheirandish Ali, Saghazadeh Amene, Rezaei Nima
Universal Scientific Education and Research Network (USERN) Office, Lorestan University of Medical Sciences, Khorramabad, Iran.
Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.
Curr Med Chem. 2025;32(10):2021-2039. doi: 10.2174/0109298673258661231003045907.
Neopterin (NEO) is an inflammatory biomarker with proposed diagnostic value in cardiovascular diseases. Some correlations have been discovered between NEO levels and the incidence, severity, and adverse outcomes of heart failure (HF). However, there are discrepancies in the results reported in the literature.
We conducted a systematic review and meta-analysis of studies comparing urinary and blood NEO concentrations between individuals with HF, cardiac insufficiency, or dilated cardiomyopathy (DCM) with control groups or those monitoring the role of NEO concentrations as a predictive marker of adverse outcomes in HF patients.
A total of 24 studies that met the inclusion criteria were reviewed. The studies demonstrated the alteration of NEO in blood or urine samples in subjects with HF, cardiac insufficiency, or DCM compared with control groups. Also, reviewing the studies suggested a link between reduced ejection fraction, higher NYHA classes, and a higher risk of adverse cardiac outcomes with increased NEO levels. The meta-analysis of three studies revealed a significant increase in serum NEO levels in HF cases compared to that in healthy controls with an effect size of 3.72 (95 % CI 0.16 to 7.28; p = 0.04).
Meta-analysis demonstrated a significant difference between serum NEO levels of HF cases and healthy subjects. This evidence implies the potential of serum NEO as a valuable diagnostic biomarker in HF patients. Also, the review of the studies revealed the prognostic potential of NEO. Further research is required to assess the usefulness of NEO as a diagnostic/prognostic biomarker for HF.
新蝶呤（NEO）是一种炎症生物标志物，在心血管疾病中具有潜在的诊断价值。已发现NEO水平与心力衰竭（HF）的发生率、严重程度及不良结局之间存在一些关联。然而，文献报道的结果存在差异。
我们对比较HF、心脏功能不全或扩张型心肌病（DCM）患者与对照组尿和血中NEO浓度的研究，或监测NEO浓度作为HF患者不良结局预测标志物作用的研究进行了系统综述和荟萃分析。
共纳入并综述了24项符合纳入标准的研究。这些研究表明，与对照组相比，HF、心脏功能不全或DCM患者血或尿样本中的NEO发生了改变。此外，对这些研究的综述表明，射血分数降低、纽约心脏协会（NYHA）分级较高以及心脏不良结局风险较高与NEO水平升高之间存在联系。对三项研究的荟萃分析显示，HF患者血清NEO水平显著高于健康对照组，效应大小为3.72（95%CI 0.16至7.28；p = 0.04）。
荟萃分析表明HF患者与健康受试者血清NEO水平存在显著差异。这一证据表明血清NEO在HF患者中具有作为有价值诊断生物标志物的潜力。此外，对这些研究的综述揭示了NEO的预后潜力。需要进一步研究以评估NEO作为HF诊断/预后生物标志物的实用性。
